Euronext

ONWARD® Medical Reaffirms Guidance, Shares 2024 Strategic Priorities, and Releases Unaudited Q4 Financial Highlights

Retrieved on: 
Friday, March 15, 2024
Blood pressure, EUR, BCI, Sale, TAP, Euronext, Spinal cord, ARC, FDA, Movement, SCI, Pharmaceutical industry

The Company expects to launch its investigational ARC-EX Therapy to improve the strength and function of the upper extremities after SCI in the US in Q4 2024.

Key Points: 
  • The Company expects to launch its investigational ARC-EX Therapy to improve the strength and function of the upper extremities after SCI in the US in Q4 2024.
  • Major associated milestones this year include FDA De Novo submission, FDA clearance, and first commercial sale.
  • The Company plans to publish its Full Year 2023 financial statements on April 25, 2024.
  • Net cash outflow in Q4, 2023 was EUR 7.0 million, consistent with the EUR 7.0M cash burn in Q3, 2023.

AB Science: New research shows that masitinib limits neuronal damage in a model of neuroimmune-driven neurodegenerative disease

Retrieved on: 
Wednesday, March 13, 2024
Neurology, Serum, EAE, Multiple sclerosis, ALS, Disease, Patient, Biomarker, Masitinib, Research, Mouse, Science, University, MD, Euronext, Alzheimer's disease, Cytokine, AN, BioRxiv, FDA, NFL, Nerve, FIRST, AFL, NDD, Guideline, Pharmaceutical industry

Findings have been published on the bioRxiv preprint service as an article entitled, ‘Masitinib limits neuronal damage, as measured by serum neurofilament light chain concentration, in a model of neuroimmune-driven neurodegenerative disease’.

Key Points: 
  • Findings have been published on the bioRxiv preprint service as an article entitled, ‘Masitinib limits neuronal damage, as measured by serum neurofilament light chain concentration, in a model of neuroimmune-driven neurodegenerative disease’.
  • The neuroprotective action of masitinib was studied in an animal model of experimental autoimmune encephalitis (EAE).
  • Results showed that masitinib can significantly lower serum NfL levels, and by extension therefore, neuronal damage, in a neuroimmune-driven neurodegenerative disease model, with concomitant reduction in pro-inflammatory cytokines and slowing of clinical symptoms.
  • Masitinib limits neuronal damage, as measured by serum neurofilament light chain concentration, in a model of neuroimmune-driven neurodegenerative disease.

Altria Enters $2.4 Billion Accelerated Share Repurchase Transactions in Connection with Closing of Offering of Anheuser-Busch InBev Stock

Retrieved on: 
Tuesday, March 19, 2024
Tobacco, Retail, Professional Services, Finance, European Economic Area, Gross metropolitan product, Goldman Sachs, ASR, ABI, Sale, ANB, ADS, AB InBev, Risk, Euronext, Annual report, Share repurchase, Security (finance)

Altria Group, Inc. (Altria) (NYSE: MO) today announces that we entered accelerated share repurchase (ASR) transactions under separate agreements with Morgan Stanley & Co. LLC and Goldman Sachs & Co. LLC on March 15, 2024, to repurchase $2.4 billion of our common stock.

Key Points: 
  • Altria Group, Inc. (Altria) (NYSE: MO) today announces that we entered accelerated share repurchase (ASR) transactions under separate agreements with Morgan Stanley & Co. LLC and Goldman Sachs & Co. LLC on March 15, 2024, to repurchase $2.4 billion of our common stock.
  • We expect the remainder of the shares to be delivered no later than the end of the second quarter of 2024.
  • The ASR transactions are part of our expanded $3.4 billion share repurchase program, which we expect to complete by December 31, 2024.
  • In addition, ABI repurchased $200 million of ordinary shares directly from us, concurrently with the completion of the offering.

Altria to Significantly Enhance Cash Returns to Shareholders Through Expanded Share Repurchase Program in Connection with Pricing of Offering of Anheuser-Busch InBev Stock; Raises 2024 Full-Year Earnings Guidance

Retrieved on: 
Thursday, March 14, 2024
Tobacco, Retail, Wine & Spirits, Health, Uncertainty, Climate change, European Economic Area, Growth, Gross metropolitan product, Exercise, MSA, EPS, Risk, Accounting, Law enforcement, Food and Drug Administration, Climate, ASR, History, Sale, Acquisition, ANB, Private sector, ADS, AB InBev, Euronext, Artificial intelligence, Investment, Annual report, Heated tobacco product, NPM, GAAP, Vision, Income tax, Information, Pandemic, Privacy, Food, Share repurchase, Security (finance)

In connection with the pricing of the offering, we announce a $2.4 billion increase to our existing $1 billion share repurchase program.

Key Points: 
  • In connection with the pricing of the offering, we announce a $2.4 billion increase to our existing $1 billion share repurchase program.
  • Our Board of Directors (Board) has authorized the expanded program, which we expect to complete by December 31, 2024.
  • Share repurchases depend on marketplace conditions and other factors, and the program remains subject to the discretion of our Board.
  • As part of the expanded share repurchase program, we expect to enter into an estimated $2.4 billion accelerated share repurchase (ASR) program.

Altria Announces Intent to Sell a Portion of its Investment in Anheuser-Busch InBev

Retrieved on: 
Wednesday, March 13, 2024
Tobacco, Retail, Wine & Spirits, European Economic Area, Gross metropolitan product, Telephone, EDGAR, ABI, Sale, ANB, ADS, Risk, Euronext, Prospectus, Morgan Stanley, Broadridge Financial Solutions, Annual report, Varick Street, Beer, 2nd Floor, Security (finance)

In addition, ABI has agreed to repurchase $200 million of ordinary shares directly from Altria, concurrently with, and conditional on, completion of the offering.

Key Points: 
  • In addition, ABI has agreed to repurchase $200 million of ordinary shares directly from Altria, concurrently with, and conditional on, completion of the offering.
  • Altria, as the selling shareholder, is offering 35 million of ABI’s ordinary shares.
  • In addition, we have agreed to a 180-day lockup with the lead underwriter for our remaining ABI shares.
  • “Over the decades of our ownership, the beer investment has provided significant income and cash returns and supported our strong balance sheet.

Worldline North America celebrates third consecutive certification as a Great Place To Work®

Retrieved on: 
Wednesday, April 3, 2024
WLN, Senior, Health, Euronext, Certification, Workplace, Drink, Management

This certification is a result of direct feedback from employees, gathered through an extensive and confidential survey about their workplace experience.

Key Points: 
  • This certification is a result of direct feedback from employees, gathered through an extensive and confidential survey about their workplace experience.
  • "We are thrilled to be certified as a Great Place To Work® aonce again, as this recognition is completely based on employees providing feedback.
  • This third consecutive certification highlights our dedication to supporting our team members in achieving fulfilling careers and highlights our employees continued desire to stay and grow with us," says Justin Passalaqua, Worldline North America Managing Director.
  • According to Great Place To Work, CertifiedTM companies have better leadership, fairer paths to promotions, reduced burnout rates, and 93% more employees look forward to work.

ONWARD® Medical Accepted to New US FDA TAP Program for Development of its ARC-BCI™ System

Retrieved on: 
Monday, March 11, 2024
SCI, Paralysis, BCI, FDA, ARC, BDD, Euronext, Risk, TAP, History, Patient, Movement, Medical device

This acceptance follows ONWARD Medical’s announcement last week that its investigational ARC-BCI System was awarded FDA Breakthrough Device Designation (BDD), a requirement for TAP consideration.

Key Points: 
  • This acceptance follows ONWARD Medical’s announcement last week that its investigational ARC-BCI System was awarded FDA Breakthrough Device Designation (BDD), a requirement for TAP consideration.
  • ONWARD Medical is only the second BCI company to be accepted into the program.
  • TAP provides ONWARD Medical with early and frequent strategic engagement from the FDA, patients, providers, and payers to facilitate more rapid development and widespread patient access to safe, effective, high-quality medical devices of public health importance.
  • “We are honored to be one of the first BCI companies included in this important program, which allows for the fastest FDA review times of new medical technology,” said ONWARD Medical CEO Dave Marver.

argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of Neurology 2024 Annual Meeting

Retrieved on: 
Thursday, March 7, 2024
OCS, Neonatal Fc receptor, Autoimmune disease, Continuity, ADAPT, CIDP, Alfa Romeo, FDA, Immunoglobulin therapy, Quality of life, NXT, PDUFA, Euronext, Risk, AAN, Clinical trial, Immunoglobulin G, GMG, Abstract, Efficacy, American Academy, Pharmaceutical industry

“We are opening a new chapter for the VYVGART portfolio,” said Luc Truyen, M.D., Ph.D., Chief Medical Officer at argenx.

Key Points: 
  • “We are opening a new chapter for the VYVGART portfolio,” said Luc Truyen, M.D., Ph.D., Chief Medical Officer at argenx.
  • These positive data from the ADHERE study have been submitted to the FDA for potential approval of VYVGART Hytrulo in CIDP with a PDUFA target action date of June 21, 2024.
  • Achievement of MSE enables significant quality of life improvements: ADAPT/ADAPT+ demonstrate that >40% of patients achieve minimal symptom expression (MSE) across both studies.
  • Patients achieving MSE experience quality of life outcomes comparable to healthy populations, suggesting MSE could be a primary goal of gMG treatment.

AB Science provides a summary of the live webcast held on March 4, 2024 giving an update on AB Science development

Retrieved on: 
Thursday, March 7, 2024
Bias, Lung compliance, NON, SCIENCE, Tracheotomy, Acute myeloid leukemia, Mast cell activation syndrome, BTK, Alzheimer's disease, ANCOVA, Azacitidine, Missionary, B cell, Riluzole, CHMP, Guideline, NOD, Sickle cell disease, ALZ, Tablet, MECOM, AML, SCD, Biomarker, DSM-IV codes, Survival, Science, Prostate cancer, Oxygen, EMA, Docetaxel, Health Canada, ISM, FDA, Masitinib, Euronext, Cell, Chromosome abnormality, OS, UPDATE, Multiple sclerosis, COVID-19, Patient, Disease, Itch, RHU, CAFS, Failure, Depression, Pharmaceutical industry

SUMMARY OF THE WEBCAST HELD ON MARCH 4, 2024 PROVIDING AN UPDATE ON AB SCIENCE DEVELOPMENT

Key Points: 
  • SUMMARY OF THE WEBCAST HELD ON MARCH 4, 2024 PROVIDING AN UPDATE ON AB SCIENCE DEVELOPMENT
    AB Science SA (Euronext - FR0010557264 - AB) is providing a summary of the live webcast held on March 4, 2024, giving an update on AB Science development.
  • Regarding Health Canada, a Notice of Deficiency-Withdrawal (NOD/w) has been issued and AB Science intends to submit a Request for Reconsideration.
  • Based on the supporting arguments and counterarguments outlined above, AB Science intends to submit a Request for Reconsideration.
  • AB Science will be free to continue the development of masitinib in SCD based on phase 2 data with biomarkers.

Seasoned Investment Banker Dan McClory Acquires Majority Stake in Brera Holdings

Retrieved on: 
Thursday, March 7, 2024
Initial public offering, Acquisition, Top Ten, Euronext, Toronto Stock Exchange, Growth, IPO, Euronext Dublin, University, Stock exchange, Euronext Growth, Seemabaddha, Executive, London Stock Exchange, Trust

DUBLIN, Ireland and MILAN, Italy, March 06, 2024 (GLOBE NEWSWIRE) -- Brera Holdings PLC (“Brera Holdings”, “Brera” or the “Company”) (Nasdaq: BREA ) announces today that its Executive Chairman, Daniel J. McClory, an experienced figure in the investment banking world, has acquired a majority stake in Brera Holdings, the first publicly-traded multi-club ownership (“MCO”) company in global football (American soccer).

Key Points: 
  • DUBLIN, Ireland and MILAN, Italy, March 06, 2024 (GLOBE NEWSWIRE) -- Brera Holdings PLC (“Brera Holdings”, “Brera” or the “Company”) (Nasdaq: BREA ) announces today that its Executive Chairman, Daniel J. McClory, an experienced figure in the investment banking world, has acquired a majority stake in Brera Holdings, the first publicly-traded multi-club ownership (“MCO”) company in global football (American soccer).
  • Mr. McClory has extensive experience founding and financing growth companies and executing equity capital markets and merger & acquisition transactions.
  • Dan's principal and advisory deals have spanned North and South America, Europe, Africa and Asia.
  • Together, we look forward to a future defined by growth, sustained innovation, and global reach, empowered by the trust and leadership of Mr. McClory and our all-star Advisory Board.”